TipRanks on MSN
Work Medical Technology Group sells new class B shares to COO’s entity, consolidating voting control
WORK Medical Technology Group LTD ( ($WOK) ) has provided an update. On December 30, 2025, WORK Medical Technology Group LTD entered into a ...
A first-of-its-kind university that offers specialized, practice oriented, academic programmes in the field of medical ...
The healthcare sector came under pressure in 2025, as federal spending cuts slashed more than $1 trillion from health programs in the biggest rollback of federal support for healthcare in U.S. history ...
HKSH Medical Group ('HKSH') and Southern University of Science and Technology ('SUSTech') officially signed a Memorandum of ...
Initiating coverage on Creative Medical Technology Holdings with a Sell rating due to early-stage pipeline and significant downside risks outweighing potential upside. The company’s pipeline includes ...
The use of 3D printing to fabricate patient-specific implants has made great strides over the years, but surgical guides and pre-operative models continue to be the most widespread application of 3D ...
WORK Medical Technology Group LTD (Nasdaq: WOK) ('WORK Medical” or the 'Company”), a supplier of medical devices in China, ...
AZoLifeSciences on MSN
How Avatar Medical's 3D technology is transforming how we visualize the human body
Avatar Medical transforms CT and MRI scans into interactive 3D models, enhancing understanding for clinicians and patients in ...
In 2026, Medtronic plans to launch a new robot to compete with a legacy market leader. This new robot is reportedly cheaper ...
In the dynamically changing healthcare landscape, innovation alone is not enough. Companies and scientists must form strategic alliances, especially in regions with complex regulatory environments.
Work Medical Technology is effectuating a reverse stock split on a 1-for-100 basis. The Chinese medical-device supplier said Wednesday the decision was made primarily to remain in compliance with ...
Shanghai Xianxiang Medical Technology Co. Ltd. has synthesized CDK2/cyclin E1 inhibitors reported to be useful for the treatment of cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results